| Microbiology | Lifetime | 35 | CH 2 | 99.38 |
| Endocrinology | Lifetime | 54 | CH 3 | 99.04 |
| Clinical Biochemistry | Lifetime | 61 | CH 1 | 98.67 |
| Infectious Diseases | Lifetime | 409 | CH 10 | 98.52 |
| Parasitology | Lifetime | 384 | CH 12 | 94.95 |
| Molecular Medicine | Lifetime | 636 | CH 8 | 65.15 |
| Microbiology | 2021-2025 | 26 | CH 1 | 97.32 |
| Infectious Diseases | 2021-2025 | 221 | CH 3 | 96.26 |
| Clinical Biochemistry | 2021-2025 | 22 | CH 2 | 93.45 |
| Epidemiology | 2021-2025 | 713 | CH 6 | 93.09 |
| Reproductive tract infections research | Lifetime | 28 | CH 2 | 99.49 |
| Legionella and Acanthamoeba research | Lifetime | 10 | CH 1 | 99.32 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 64 | CH 4 | 99.55 |
| Urinary Tract Infections Management | Lifetime | 102 | CH 1 | 99.12 |
| SARS-CoV-2 detection and testing | Lifetime | 79 | CH 1 | 97.94 |
| Streptococcal Infections and Treatments | Lifetime | 197 | CH 5 | 98.67 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 557 | CH 13 | 98.20 |
| Gut microbiota and health | Lifetime | 439 | CH 5 | 98.55 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 367 | CH 8 | 98.52 |
| Yersinia bacterium, plague, ectoparasites research | Lifetime | 154 | CH 2 | 97.43 |
| Mycobacterium research and diagnosis | Lifetime | 494 | CH 10 | 97.58 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 337 | CH 4 | 97.49 |
| Microbial infections and disease research | Lifetime | 512 | CH 11 | 96.82 |
| Amoebic Infections and Treatments | Lifetime | 214 | CH 4 | 95.65 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 700 | CH 20 | 97.12 |
| Vibrio bacteria research studies | Lifetime | 540 | CH 17 | 96.37 |
| Bacterial biofilms and quorum sensing | Lifetime | 725 | CH 19 | 96.26 |
| Infections and bacterial resistance | Lifetime | 113 | CH 3 | 95.31 |
| Heme Oxygenase-1 and Carbon Monoxide | Lifetime | 543 | CH 9 | 94.77 |
| Vector-borne infectious diseases | Lifetime | 862 | CH 14 | 95.57 |
| Syphilis Diagnosis and Treatment | Lifetime | 356 | CH 8 | 94.15 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 366 | CH 11 | 91.93 |
| Bartonella species infections research | Lifetime | 160 | CH 5 | 90.54 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 868 | CH 8 | 79.94 |
| Actinomycetales infections and treatment | Lifetime | 692 | CH 10 | 75.36 |
| Whipple's Disease and Interleukins | Lifetime | 967 | CH 21 | 49.16 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 44 | CH 2 | 97.93 |
| Urinary Tract Infections Management | 2021-2025 | 58 | CH 1 | 95.99 |
| Reproductive tract infections research | 2021-2025 | 52 | CH 1 | 97.02 |
| SARS-CoV-2 detection and testing | 2021-2025 | 241 | CH 6 | 95.07 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 666 | CH 7 | 82.64 |
| Data-Driven Disease Surveillance | 2021-2025 | 951 | CH 18 | 57.57 |
| Plant and fungal interactions | 2021-2025 | 529 | CH 6 | 52.85 |
